VRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-03-28), Vertex Pharmaceuticals's current share price is $418.01. Vertex Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $5.86. Vertex Pharmaceuticals's Shiller PE Ratio for today is 71.33.
The historical rank and industry rank for Vertex Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:
During the past years, Vertex Pharmaceuticals's highest Shiller PE Ratio was 8209.67. The lowest was 63.32. And the median was 90.54.
VRTX's Shiller PE Ratio is ranked worse thanE10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Vertex Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $3.710. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $5.86 for the trailing ten years ended in Dec. 2023.
The historical data trend for Vertex Pharmaceuticals's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vertex Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Vertex Pharmaceuticals's Shiller PE Ratio for today is calculated as
Shiller PE Ratio | = | Share Price | / | E10 |
= | 418.01 | / | 5.86 | |
= | 71.33 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:
For example, Vertex Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 3.71 | / | 129.4194 | * | 129.4194 | |
= | 3.710 |
Current CPI (Dec. 2023) = 129.4194.
Vertex Pharmaceuticals Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201403 | -1.000 | 99.695 | -1.298 |
201406 | -0.680 | 100.560 | -0.875 |
201409 | -0.720 | 100.428 | -0.928 |
201412 | -0.740 | 99.070 | -0.967 |
201503 | -0.830 | 99.621 | -1.078 |
201506 | -0.780 | 100.684 | -1.003 |
201509 | -0.390 | 100.392 | -0.503 |
201512 | -0.310 | 99.792 | -0.402 |
201603 | -0.170 | 100.470 | -0.219 |
201606 | -0.260 | 101.688 | -0.331 |
201609 | -0.160 | 101.861 | -0.203 |
201612 | 0.130 | 101.863 | 0.165 |
201703 | 0.990 | 102.862 | 1.246 |
201706 | 0.070 | 103.349 | 0.088 |
201709 | -0.410 | 104.136 | -0.510 |
201712 | 0.390 | 104.011 | 0.485 |
201803 | 0.810 | 105.290 | 0.996 |
201806 | 0.800 | 106.317 | 0.974 |
201809 | 0.500 | 106.507 | 0.608 |
201812 | 5.970 | 105.998 | 7.289 |
201903 | 1.030 | 107.251 | 1.243 |
201906 | 1.030 | 108.070 | 1.233 |
201909 | 0.220 | 108.329 | 0.263 |
201912 | 2.230 | 108.420 | 2.662 |
202003 | 2.290 | 108.902 | 2.721 |
202006 | 3.180 | 108.767 | 3.784 |
202009 | 2.530 | 109.815 | 2.982 |
202012 | 2.300 | 109.897 | 2.709 |
202103 | 2.490 | 111.754 | 2.884 |
202106 | 0.260 | 114.631 | 0.294 |
202109 | 3.280 | 115.734 | 3.668 |
202112 | 3.000 | 117.630 | 3.301 |
202203 | 2.960 | 121.301 | 3.158 |
202206 | 3.130 | 125.017 | 3.240 |
202209 | 3.590 | 125.227 | 3.710 |
202212 | 3.150 | 125.222 | 3.256 |
202303 | 2.690 | 127.348 | 2.734 |
202306 | 3.520 | 128.729 | 3.539 |
202309 | 3.970 | 129.860 | 3.957 |
202312 | 3.710 | 129.419 | 3.710 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey M Leiden | director | 15 N BEACH ROAD, HOBE SOUND FL 33455 |
Wagner Charles F Jr | officer: EVP & Chief Financial Officer | C/O MILLIPORE CORP, BILLERICA MA 01820 |
Reshma Kewalramani | director, officer: CEO & President | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Stuart A Arbuckle | officer: EVP, COO | VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139 |
Amit Sachdev | officer: SVP, Public Policy,Gov Affairs | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
David Altshuler | officer: EVP, Global Research and CSO | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
Carmen Bozic | officer: EVP and CMO | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Bruce I Sachs | director | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Sangeeta N. Bhatia | director | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Michel Lagarde | director | 450 LEXINGTON AVE., 31ST FLOOR, NEW YORK NY 10017 |
Atkinson Edward Morrow Iii | officer: EVP, Chief Technical Ops. Off. | C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104 |
Ourania Tatsis | officer: EVP, Chief Reg. & Quality Off. | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Terrence C Kearney | director | IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045 |
Kristen Ambrose | officer: SVP & Chief Accounting Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210 |
Bastiano Sanna | officer: EVP, Cell & Genetic Therapies | C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210 |
From GuruFocus